key: cord-0911150-nf2ioo4j
authors: Ribitsch, Werner; Stelzl, Evelyn; Kessler, Harald H; Eller, Kathrin
title: Prolonged detection of SARS-CoV-2 RNA in chronic hemodialysis patients
date: 2021-10-20
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab211
sha: 495770bf91e5a20c735b1fc6b0b0d28bec02041a
doc_id: 911150
cord_uid: nf2ioo4j

nan

Patients on maintenance hemodialysis exhibit a high risk of an adverse outcome after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reported case fatality rates vary from 16-32% [1] . Moreover, patients receiving in-center hemodialysis are particularly vulnerable to SARS-CoV-2 infection due to the impossibility to self-isolate themselves. This situation is further exacerbated by recent reports revealing a diminished immune response both after recovery from COVID-19 and vaccination against SARS-CoV-2

in the dialysis population [2, 3] .

In this regard, we want to add another aspect to be considered by presenting two cases of exceptional long detectability of SARS-CoV-2 RNA in chronic hemodialysis patients.

The first patient is a 61 year old woman who was admitted to hospital for evaluation of (Table 1) .

A 55 year old male patient on maintenance hemodialysis due to diabetic nephropathy After an extended convalescent period, he was finally discharged on day 63 and since then remains SARS-CoV-2 negative (Table 2) . infections due to their immunocompromised status. Furthermore, our cases demonstrate that a single negative SARS-CoV-2 PCR test is not enough to decide whether a patient has to be isolated or not.

The patients gave informed consent to publish their case. 

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

Kinetics of Anti-SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection

Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won

Food and Drug Administration

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

College of American Pathologists (CAP) Microbiology Committee Perspective: Caution must be used in interpreting the Cycle Threshold